Extended Data Fig. 2: Gene alterations at baseline with response to HER3-DXd.
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
(a) Oncoplot showing non-synonymous point mutations, indels, homozygous deletions, loss of heterozygosity (LOH) and low, medium, and high-level amplifications in the set of 73 genes of interest, according to treatment response: responders (confirmed CR, PR), n = 26; non-responders (SD, PD, NE), n = 17.Blood samples were available for all patients. (b) Oncoplot showing non-synonymous point mutations, indels, homozygous deletions, loss of heterozygosity (LOH) and low, medium, and high-level amplifications in the set of 73 genes of interest, according to CBR: CBR (confirmed CR, PR, SD > 6 months; n = 27; non CBR (unconfirmed PR, SD < 6 months, PD; n = 16). Blood samples were available for all patients.
